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Abstract 
The great success of immunotherapy is paving the way for a new era in cancer treatment and is 
driving major improvements in the therapy of patients suffering from a range of solid tumors. 
However, the choice of the appropriate tumor antigens to be targeted with cancer vaccines and T-
cell therapies is still a challenge. Most antigens targeted so far have been identified on the tumor 
bulk and are expressed on differentiated cancer cells. The discovery of a small population of cancer 
stem cells (CSC), which is refractory to most current therapies and responsible for the development 
of metastasis and recurrence, has made it clear that the ideal targets for immunotherapies are the 
antigens that are expressed in CSC and play a key role in their function. Indeed, their 
immunotargeting would enable the eradication of CSC to be performed, thus eliminating the tumor 
source. We call these antigens “CSC oncoantigens”. 
Herein, we summarize the controversial nature of breast CSC, discuss why they represent good 
candidates for cancer immunotherapy, and review the CSC antigens that have been used as targets 
for CSC immunotargeting this far. Moreover, we describe the pipeline that we have developed for 
the identification of fresh CSC oncoantigens, and present the pre-clinical results obtained with 
vaccines that target some of these antigens.  
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1. Introduction 
Breast cancer is the leading cause of cancer death in women globally, accounting for 11.6% of all 
new cancer diagnoses in 2018 and almost 630,000 deaths (Global Cancer Observatory, 
https://gco.iarc.fr/). Cancer metastasis and resistance to therapy are significant hurdles to the 
successful treatment of breast cancer, especially considering that 80% of breast cancer deaths are 
due to metastases that develop despite therapy [1]. As compared to other breast cancer subtypes, 
women with Her2+ and triple negative breast cancer (TNBC) have the highest rates of early cancer 
recurrences and metastases. Moreover, the frequent development of resistance to anti-Her2 
targeting therapies in Her2+ breast cancer patients and the lack of defined molecular targets for 
TNBC strongly limit the therapeutic options available, leaving cytotoxic chemotherapy as the main 
therapeutic approach. The success that immune checkpoint blockade has had in ameliorating the 
prognosis of patients with advanced solid tumors, such as melanoma and non-small cell lung cancer 
(NSCLC) [2], has recently opened up new perspectives in the management of breast cancer. 
Multiple clinical trials have been performed on immune checkpoint inhibitors that are specific for 
CTLA4, PD1 and PD-L1 and that are either administered as single agents, or in combination with 
either the anti-Her2 humanized monoclonal antibody, Trastuzumab, in Her2+ or with chemotherapy,  
in TNBC [3, 4]. In March 2019, the Food and Drug Administration (FDA) approved the use of the 
anti-PD-L1 antibody Atezolizumab in combination with nab-paclitaxel for the frontline treatment of 
patients with unresectable locally advanced or metastatic PD-L1+ TNBC. This approval was based 
on the results of the Impassion130 trial, in which a statistically significant increase in median 
progression-free survival was found in patients with PD-L1+ tumor-infiltrating immune cells [4]. 
Although this study offers definitive evidence that immunotherapy is efficacious, at least for a 
subset of patients with TNBC, these findings also highlight the need to develop new combination 
strategies for patients that have metastatic breast cancer with lower immunogenicity.  
In recent years, ever growing amounts of data have been gathered to support the hypothesis that 
cancer stem cells (CSC) - a small population of cells endowed with stem-like properties, and tumor-
initiating and immune regulatory abilities – play a key role in tumor development, dissemination 
and resistance to therapy [5]. Albeit controversial, this hypothesis implies that successful anti-tumor 
treatments should rest on the elimination, or permanent functional suppression, of CSC. The 
identification of suitable molecular targets that are expressed by CSC may thus be critical for the 
development of more effective anticancer therapies for use as either single agents, or to improve the 
response to chemo- and radiotherapy and to immune checkpoint blockade. In this context, anti-
cancer vaccination may be a valid option.  
We have previously coined the term “oncoantigen” [6] to indicate tumor antigens that are suitable 
and effective anti-cancer vaccination targets. In this work, we expand this concept in light of a new 
understanding of the importance of CSC in breast cancer progression and discuss a variety of 
immune-targeting strategies that may pave the way for the development of new combinatorial 
therapies for the treatment of metastatic breast cancer patients.  
 
2. Controversy and consensus on CSC 
CSC are functionally defined by their ability to both self-renew and give rise to cells with non-stem 
cell characteristics that recapitulate the parental tumor, including the original cellular heterogeneity 
found within it, upon transplantation [7, 8]. Despite considerable experimental evidence to suggest 
that most human cancers hold CSC, many aspects of their biology are still controversial, including 
their origin and phenotypic properties [9]. 
It has been proposed that CSC either originate from normal adult stem cells or more differentiated 
progenitor cells undergoing transformation [10]. This idea is well supported in the case of breast 
CSC (BCSC), since the breast, unlike many other organs, primarily develops postnatally and 
therefore requires a reservoir of adult stem cells that serve both homeostatic and developmental 
functions [11]. The breast is composed of a bi-layered epithelium that contains luminal and basal 
epithelial cells; the former line the mammary gland ductal structures, while the latter surround 
luminal cells and are in contact with the basement membrane, which separates the parenchyma from 
the stromal component of the tissue. Within the basal compartment, reside multipotent mammary 
stem cells (MaSC), which are responsible for the generation of progenitor cells and differentiated 
cells of both lineages. This hierarchically organized tissue is constantly remodeled [11]. In 
particular during puberty, hormones, growth factors and microenvironmental signaling cues from 
various surrounding non-epithelial cells [12, 13], induce the proliferation of MaSC and their 
progeny, leading to the construction of the branching ductal epithelium and the development of the 
mammary tree [14]. Moreover, each menstrual cycle and pregnancy, over the reproductive lifespan 
of a woman, leads to dramatic changes in the mammary epithelium, which repeatedly expands and 
regresses, and thus requires MaSC and progenitors to be able to differentiate into the different cell 
lineages. However, the longevity and self-renewal properties of MaSC and progenitors expose them 
to a high risk of oncogenic transformation, making them possible cells-of-origin for BCSC, and, 
more generally, of breast cancer [13, 15]. Indeed, limiting MaSC and progenitors has been proposed 
as a primary preventive option for women who are at high risk of developing breast cancer via 
inherited mutations [14].  
Nevertheless, there is an ever growing amount of evidence to suggest that CSC do not necessarily 
arise from normal stem cells, but that they can also derive from normal non-stem epithelial cells 
that acquire self-renewal abilities after transformation, or from de-differentiated cancer cells [10]. 
This concept is supported by the observation that agents, such as transforming growth factor  and 
hypoxia, can induce an epithelial-to-mesenchymal transition (EMT) in the bulk of human breast 
tumor cells and lead to an increase in the number of cells showing BCSC features [16]. This 
concept also implies that CSC are not necessarily rare and that they may exist in a variety of states, 
which is a demonstration of their cellular plasticity [17]. 
Another central issue in the controversy over the CSC hypothesis is the lack of universally defined 
cell-surface markers. Indeed, although many markers that are indicative of the CSC phenotype have 
been identified, they differ over the various tumor types and also among tumors of the same 
histotype that come from different patients and/or lesions [7]. In the case of human BCSC, a 
combination of high CD44 and low, or absent, CD24 expression have been proposed as markers, 
together with the expression of aldehyde dehydrogenase (ALDH) activity [5]. These markers are 
not sufficient alone to define CSC. However, they are useful for CSC enrichment and subsequent 
functional analyses. Indeed, the heterogeneity of BCSC and the dynamic, reversible transition from 
BCSC to most differentiated phenotypes has been demonstrated thanks to BCSC enrichment on 
these markers [18].  
Independently from CSC origin and phenotypic properties, the reversible transition between the 
different states that characterize their plasticity is able to explain the minimal residual disease [19], 
and the metastasis cascade [20], of most tumors, including breast cancer. When CSC are in the 
relatively quiescent EMT-state, they are endowed with the capacity for tissue invasion and 
dissemination to the metastatic sites; here they stay in a dormant state with occasional cell divisions 
[21, 22], before reawakening and, thanks to reversion to a more proliferative epithelial-like state 
(mesenchymal-to-epithelial transition), giving rise to overt disease [23, 24]. These disseminated 
cancer cells (DCC) are the seeds of recurrences and metastases and can arise at several stages of 
cancer progression, including premalignancy [21, 22]. Indeed, DCC display self-renewal ability, 
multipotency, immune-evasiveness and resistance to targeted and conventional therapies. The latter 
are conferred by CSC “robustness” [19], which refers to a number of biological features, including 
resistance to T-cell cytotoxicity and redox stress, an enhanced ability to mediate the efflux of 
anticancer drugs, to rapidly repair damaged DNA, to undergo metabolic reprogramming and to 
survive in a hypo-nutrient microenvironment [5]. The consequence of robustness is that most anti-
cancer treatments can induce an enrichment in CSC in the primary tumor, while sparing DCC.  
Therefore, moving past the controversies on CSC biology, a consensus has been reached on the 
necessity to develop anti-cancer treatments that are specifically designed to target these cells [25]. 
 
3. CSC immunogenicity  
The key role played by CSC in cancer progression and resistance to current therapies, together with 
the renewed enthusiasm for immunotherapeutic approaches, have driven scientists to evaluate the 
possibility of developing immunotherapies that target CSC. 
The immune-evasive and immunosuppressive features of CSC are certainly a hurdle to the 
possibility of inducing efficient immune responses that may eradicate them. Indeed, CSC from 
breast cancer and many other solid tumors express low levels of MHC class I molecules [26], and 
defects in the antigen processing machinery have been identified in CSC from glioblastoma [27], 
suggesting that CSC possess an ability to escape from cytotoxic T-cell killing. Moreover, they 
secrete immunosuppressive cytokines, such as TGF-, IL-10 and IL-4, that can inhibit T- and NK-
cell activation [28, 29]. Finally, the high expression of PD-L1 and other immune-checkpoint 
molecules has been observed on CSC from glioblastoma [30], breast and colorectal cancer [31], 
further suggesting that CSC bear a lower susceptibility to immune-cell killing than differentiated 
cancer cells.  
However, in spite of these, rather dismal, assertions, it has recently been reported that CSC might be 
immunogenic in certain settings. Data from immunocompetent mice, in preclinical ex-vivo and in 
vivo experiments, have demonstrated the feasibility of CSC immunotargeting. The first evidence 
came from a study showing that the vaccination of mice with dendritic cells (DC), which were 
loaded with lysates from syngeneic melanoma or NSCLC CSC, was able to induce a specific anti-
CSC humoral and cellular immune response. Most importantly, vaccine-induced antibodies and T 
cells both conferred better anti-tumor immunity than vaccination with DC that were loaded with 
bulk-tumor cells, suggesting that CSC are a better source of antigens than differentiated tumor cells 
[32]. These encouraging results have led to the development of several clinical trials that use CSC 
lysates- or mRNA-loaded DC to vaccinate patients that bear ovarian, breast, lung, pancreatic, 
colorectal and liver cancers. The currently available results demonstrate that anti-CSC vaccination 
did not induce strong side effects, but that it elicited measurable and specific anti-tumor immune 
responses, thus proving its safety and suggesting that cancer patients may benefit from anti-CSC 
vaccination [33-35]. Despite the successes being reported in these clinical trials, it must be 
mentioned that DC-based vaccination presents many drawbacks; it is a cost- and time-consuming 
patient-specific treatment, and a great deal of effort is still required to standardize it. Indeed, the 
best DC subsets, strategies for the loading of tumor antigens, and administration routes and doses of 
administration, have yet to be defined [36]. 
An alternative strategy is that of targeting a specific CSC antigen that is shared by a number of 
tumor histotypes and patients, by means of chimeric antigen receptor (CAR)-T cells or vaccines. 
The selection of a specific CSC antigen that can activate an anti-cancer immune response, rather 
than the use of the entire CSC-antigen repertoire, would prevent the efficacy of the treatment 
becoming diluted [37]. CAR-T cells that target a number of different CSC antigens are under 
investigation in pre-clinical models and have provided promising results [38, 39]. However, the 
limits of this approach are its cumbersome and expensive preparation, which is based on the use of 
patient-derived T-cells, together with the induction of major side effects, including cytokine release 
syndrome [40].  Broader applicability coupled with easier and more cost-effective production are 
the advantages of gene- and protein-based vaccines. In both cases, CAR-T cells and vaccines, the 
identification and selection of appropriate CSC targets is of paramount importance. 
Several studies have demonstrated that some tumor antigens are preferentially expressed by 
differentiated cancer cells or by CSC, while others are present on both types of cancer cells [5]. It is 
worth noting that immunotherapies directed against antigens that are only expressed on 
differentiated cancer cells would induce tumor shrinkage, but that this would be accompanied by 
the enrichment of CSC clones that give rise to recurrence and metastases. On the other hand, 
vaccination against antigens that are exclusively expressed by CSC would not be effective against 
more differentiated cells. Moreover, both types of vaccination will stimulate the inherent plasticity 
of the tumor. Therefore, to achieve tumor eradication the ideal vaccination targets are those present 
on differentiated cancer cells and overexpressed in CSC [5, 41].  
Numerous different immunotherapeutic approaches to preclinical models using CSC markers, such 
as CD133, CD44, ALDH, EpCam, as antigenic targets, have been attempted [42-45]. Although 
many of these play an important role in CSC function, they do not represent ideal targets as most of 
them are also expressed on normal stem cells. The two sides of this coin are the low 
immunogenicity of these self-tolerated antigens and, when tolerance is effectively broken by 
vaccination, the possibility of severe side effects [46]. Contrary to CSC markers, antigens that are 
generated by either DNA alterations [47], or mRNA alternative splicing [48, 49], which occur in 
cancer cells and/or in CSC - the so called neoantigens – display tumor-specific expression. The 
absence of central immune tolerance against them increases the probability that they can induce an 
effective T-cell response, while their absence of expression on normal tissues decreases the risk of 
side effects that would be mediated by on-target immune responses to healthy organs  [47]. 
Although neoantigens are surely a promising source of immunogens for cancer immunotherapy, 
their existence and distribution on CSC is still unclear. Indeed, a study on colorectal cancer patients 
demonstrated that CSC do not contain more neoantigens than their differentiated counterparts [50], 
suggesting that the presence of neoantigens on CSC strictly depends on the patient’s tumor 
mutational burden. Moreover, since most mutations occur in genes that do not play a pivotal role in 
either carcinogenesis or CSC maintenance, their use as vaccination targets may lead to tumor 
immunoediting [51], and to the expansion of clones that are deficient in the vaccine-coded antigen 
[52].  
To avoid immunoselection, vaccination should be performed against antigens that we have 
previously defined as “oncoantigens” [6, 52-54], and that, in the case of CSC, should play a pivotal 
role in self-renewal and other vital CSC biological functions. In particular, oncoantigens that are 
expressed on CSC plasma-membranes, which could be targeted by both cell- and antibody-
mediated immune responses, may be the best choice [54]. Vaccine-induced antibodies would allow 
the eradication of CSC to occur despite their ability to: i) escape T-cell recognition by 
downregulating MHC class I molecules or antigen-processing machinery [26]; ii) block T-cell 
activation through the up-regulation of checkpoint molecules [55-57] (Conti et al., unpublished 
results); and/or iii) escape NK cell cytotoxicity, as observed in some tumors [58]. 
It is conceivable that a high frequency of CSC oncoantigens may be found among genes that display 
a high expression level in CSC and lower expression in differentiated cancer cells; these 
oncoantigens are more likely to have a functional role in CSC biology [59]. An evaluation of 
differential antigen expression in CSC and differentiated cancer cells may therefore lead to the 
identification of new CSC oncoantigens for the development of anti-cancer vaccines.  
Comparisons of the transcriptomic profiles of CSC and more differentiated cells from lung and 
colon cancers have demonstrated that many cancer testis (CT) antigens are overexpressed in CSC 
[60, 61]. Since these CT antigens are normally expressed only in germ line cells, which do not 
express MHC molecules, their immunotargeting should be effective in inducing specific T-cell 
responses without major side effects [62]. Indeed, many clinical trials of vaccination with CT 
antigens have been performed in a variety of cancers, often giving positive results, thus suggesting 
that CT antigens may be promising targets for the development of anti-CSC therapies. 
 
4. BCSC antigens identification and immunotargeting 
Despite this promise, only a minority of CT antigens (such as MAGEA12, PA17, PLU‐1 and 
TEX15) have been found in breast cancer, and these have shown similar expression levels in BCSC 
and differentiated cancer cells [61]. Their use in breast cancer immunotherapy has therefore been 
very limited so far; two clinical trials with MAGE-A- and NY-ESO-1-based vaccines are currently 
ongoing [63], while a phase I clinical trial of vaccination with 5 different CT antigenic peptides in 
advanced breast cancer patients demonstrated tumor regression in 60% of patients [64].  
Another example of BCSC oncoantigens can be found in Cripto-1, a GPI-anchored cell-surface 
protein that is an oncofetal protein, a class of antigens that play important roles in cancer 
progression and whose expression is typically limited to embryonic development. Although the 
prototypical member of this class, the carcinoembryonic antigen, is not linked to cancer stemness 
[59], we have demonstrated that Cripto-1 is expressed in Her2+ and TNBC BCSC and mediates 
their self-renewal, migration and EMT [65]. Vaccination with a DNA plasmid that codes for the 
full-length Cripto-1 oncoantigen was found to successfully impair tumor growth and decrease lung 
metastases both in mice bearing TNBC transplantable tumors and in Her2-neu transgenic mice that 
develop autochthonous mammary cancers [65].  
Other BCSC oncoantigens have been identified, by our group, using a modified pipeline that we 
had originally developed for the identification of oncoantigens in the bulk of breast tumors [52].  
This method consists of a high-throughput analysis of the transcriptome of BCSC-enriched 
tumorspheres, in comparison with that of their more differentiated counterparts, in order to identify 
a gene signature that is linked to cancer cell stemness. These genes are then prioritized according to 
their association with poor prognosis in breast cancer patients, with reference to public data sets. 
The top-ranked genes are then validated, first via in vitro studies to verify their role in BCSC self-
renewal and survival, and then, in vivo by immunizing tumor-bearing mice with DNA vaccines that 
target them (Figure 1).  
The application of this pipeline to Her2+ and TNBC breast cancer cells enabled us to find novel 
potential targets for diagnostic BCSC detection, pharmacological treatments and immunotherapy. 
Indeed, we discovered that BCSC from murine and human TNBC express high levels of teneurin 
transmembrane protein (TENM) 4, a large type II transmembrane glycoprotein belonging to a 
family of four (TENM1 through TENM4) pair-rule proteins that are involved in the development of 
the central nervous system and in the organogenesis of additional tissues [42,43]. Recent evidence 
has demonstrated the dysregulated expression of teneurins in human tumors and strongly suggests 
that they functionally contribute to human carcinogenesis [66]. TENM4 up-regulation in BCSC, 
together with the significant impairment of their tumorsphere-forming ability when TENM4 is 
silenced (Quaglino et al., unpublished results), strengthen its possible role in BCSC self-renewal. 
We are now actively working on the elucidation of TENM4’s role in TNBC progression and its 
suitability as an immunotherapy target. 
Our pipeline has also been applied to BCSC from a mouse Her2+ mammary cancer cell line, leading 
to high expression levels of Scavenger Receptor Class A Member 5 (SCARA5), a transmembrane 
receptor that mediates the import of L-ferritin into cells, and thus contributes to iron uptake [67], 
being found. The overexpression of SCARA5 on BCSC may be due to their increased need for iron, 
which is important for self-renewal [68]. Although SCARA5 plays a key role in BCSC maintenance 
and its expression has been found in many breast cancers [69], it is not an ideal target for 
immunotherapy since it is constitutively expressed by epithelial cells in the gastrointestinal tract, 
gall bladder and testis [70], and by hepatocytes [71]. However, its ability to bind ferritin makes 
SCARA5 an ideal target for nanotheranostic agents [72]. Multiple studies have explored the use of 
ferritin nanocages as imaging- and drug-delivery systems for the diagnosis and treatment of tumors 
[73, 74]. We have developed a ferritin-based theranostic system containing a magnetic resonance 
imaging contrast agent (Gd-HPDO3A) and curcumin, which is a safe and natural therapeutic 
molecule endowed with strong antitumor effects. It was demonstrated that the system targeted 
BCSC, inducing cancer regression in mouse models. This may pave the way for the clinical 
application of theranostic systems that can simultaneously eliminate BCSC and allow to follow the 
response to treatment [67]. 
Other interesting oncoantigens that we have found to be overexpressed in BCSC are Toll-like 
Receptor (TLR) 2 and xCT, which is the light chain of the heterodimeric amino-acid transporter 
system xC- [75].  
Multiple genetic alterations that lead to the activation of the TLR2/MyD88 pathway have been 
identified in human breast and colon cancers. Of these, the amplifications of the gene coding for 
TLR2’s downstream effector IRAK1 (found in 23.8% of breast cancers) and various mutations that 
produce constitutively active forms of TLR2 [76].  In BCSC, the activation of TLR2, a type I 
transmembrane protein that belongs to the pattern recognition receptor family, induces the 
production of Interleukin (IL)-6, Tumor growth factor (TGF)- and VEGF. These factors act in an 
autocrine/paracrine manner to activate the STAT3 and Smad3 signaling pathways, thus promoting 
BCSC survival, proliferation, EMT and invasion [77]. These observations are of particular 
importance in light of the fact that BCSC also secrete high-mobility group box (HMGB)1, which 
binds and activates TLR2 [77];  BCSC thus foster their own self-renewal. Indeed, TLR2 inhibition 
strongly decreases tumor growth and metastases in preclinical mouse models of breast cancer [77]. 
In addition, HMGB1 is actively secreted by inflammatory cells, and can be passively released by 
tumor cells during the immunogenic cell death that is induced by radiotherapy and chemotherapy 
[78, 79]. In particular, HMGB1 is released into the tumor microenvironment after neoadjuvant 
chemotherapy in breast cancer patients [79], and high HMGB1 levels are associated with disease 
progression during neoadjuvant chemotherapy in TNBC patients [80]. TLR2 may therefore be a 
good BCSC target. Furthermore, TLR2 can be activated by pathogen-associated molecular patterns. 
It has recently been demonstrated that there exists a specific microbiota in the mammary gland, and 
some studies have identified that normal and neoplastic samples show differences in its amount and 
composition [81]. Moreover, bacterial-induced mastitis, infections and bacterial contamination after 
tumor surgery represent risk factors for the development of breast cancer metastases [82]. We are 
therefore currently evaluating whether breast dysbiosis in breast cancer patients might lead to an 
increase in pathogens that are able to activate TLR2 on BCSC, thus promoting their self-renewal, 
tumor progression and recurrence [83]. It is worth noting that the clinical applicability of TLR2 
immunotargeting is being fostered by ongoing clinical trials, which are being performed using a 
humanized anti-TLR2 antibody (NCT02363491) and a synthetic TLR2/4 antagonist 
(NCT02995655), into hematologic malignancies.   
xCT, the light chain of the heterodimeric amino-acid transport system xC- [75], is a 12-pass 
transmembrane protein that mediates the import of cystine, in exchange with glutamate, thus 
contributing to the synthesis of the antioxidant molecule glutathione [84]. Exported glutamate 
however, potentiates oncogenic signaling by acting upon selective receptors that are expressed by 
cancer cells, and induces the autocrine/paracrine activation of the Rab27a-dependent recycling of 
the transmembrane matrix metalloprotease 9 (MMP9) to promote invasion [85, 86]. In virtue of its 
protective function against reactive oxygen species and its role in invasiveness, xCT is expressed in 
many cancer cells, and upregulated in CSC [87]. In particular, increased xCT expression has been 
correlated with breast cancer invasiveness [86], and EMT [88]. Interestingly, xCT is stabilized by 
physical interaction with the splice variant of CD44 and with MUC1, which are tumor antigens 
whose expression has been reported on BCSC [89-92], and which are currently under investigation 
as targets for immunotherapy in preclinical [45], and clinical trials for breast cancer [93]. Several 
authors have advocated the use of xCT as a therapeutic target for pharmacological inhibition and a 
variety of compounds have been investigated, including erastin [94], and the FDA-approved drugs 
sulfasalazine (SAS) [95], and sorafenib [94]. However, erastin and SAS are insoluble under 
physiological conditions, as well as having poor metabolic stability and pharmacokinetics, 
preventing their reliable use in vivo; some improved analogs are currently under development [94]. 
In addition, SAS and sorafenib display low specificity for xCT, and are known for their ability to 
inhibit NFkB and various kinases, respectively, and to induce significant side effects [94, 96]. 
Therefore, new ways to specifically target xCT need to be developed for clinical use and we 
havedemonstrated that immunotherapy is a feasible option. Indeed, our in vivo preclinical studies in 
breast cancer mouse models, using different vaccination strategies (DNA-, VLP-, and BoHV-4-
based vaccines) [87, 97-99], have demonstrated that all of the vaccine formulations were able to 
induce a potent anti-xCT humoral response, impairing tumor growth and lung metastasis, without 
inducing overt signs of autoimmunity. Immunization in B-cell deficient mice showed no therapeutic 
response [97], demonstrating that vaccine-induced xCT antibodies were, in effect, the major 
therapeutic effectors. IgG that were isolated from the sera of vaccinated mice inhibited xCT 
function [97-99], and breast cancer cell invasiveness in vitro, while also increasing chemotherapy 
sensitivity both in vitro and in vivo [97]. The combination of xCT vaccination and chemotherapy 
synergistically reduced metastatic disease, compared to mice that were treated with either therapy 
alone [97]. Moreover, in vitro and in vivo studies have clearly demonstrated that xCT inhibition acts 
both by directly hampering CSC self-renewal and survival and by increasing cell sensitivity to 
chemotherapeutic drugs. Taken together, these results pave the way for the translatability of xCT 
immunotargeting in the context of adjuvant and neoadjuvant settings in combination therapies for 
breast cancer patients.  
 
Conclusions: 
CSC are considered to be the cause of tumor development and the drivers of therapeutic resistance 
in most solid tumors. Harnessing the host immune system to target CSC and cure cancer patients is 
an attractive challenge for scientists. To this end, the careful selection of CSC molecular targets and 
the complete disclosure of the mechanisms that underlie CSC immunoevasive features are 
mandatory. The majority of anti-cancer vaccines and CAR-T cells have so far been directed at 
antigens that are expressed by the differentiated cancer cells that constitute the tumor bulk, thus 
sparing CSC. However, CSC eradication requires the development of immunotherapies directed 
against the antigens that are overexpressed in CSC. In this regard, we suggest that successful 
vaccines and CAR-T for the treatment of breast cancer should be directed at antigens that are 
overexpressed in BCSC and that play a key role in their self-renewal and vital biological functions, 
“BCSC oncoantigens”, in order to avoid the immune selection of antigen-deficient BCSC clones. 
Moreover, in order to overcome the loss of antigen presentation that characterizes most BCSC, the 
most advantageous targets would be the oncoantigens that are expressed on BCSC plasma 
membranes, which can therefore be targeted by vaccine-induced antibodies and CAR-T. Finally, 
choosing oncoantigens that do not display CSC-restricted expression, but which are rather shared 
with differentiated cancer cells, would allow the hurdle of CSC plasticity and intratumor 
heterogenicity to be bypassed. 
The development of methods and pipelines for the identification of new BCSC oncoantigens, such 
as the one we propose in this review, have allowed the scientific community to make step forwards 
in the generation of new CSC-targeting immunotherapies. However, many caveats remain to be 
resolved if they are to be successfully applied in clinical trials. For example, the choice of the 
correct time window for treatment is crucial. Data from clinical trials have highlighted that CSC 
pharmacological inhibition is almost ineffective when applied to advanced cancers. Indeed, 
refractory or relapsing tumors that have already been exposed to previous treatments often contain a 
high frequency of CSC [100], which are endowed with robustness [19]. Moreover, the strong 
immunosuppressive microenvironment [101], which is typical of these tumors, negatively impacts 
upon the efficacy of vaccine-elicited immune responses and CAR-T cell. However, CSC 
immunotargeting may be of great clinical significance when applied in the adjuvant setting, as it 
would be combatting against a limited number of CSC that remain in the primary tumor site and of 
DCC in the metastatic organs. This would allow this cell population, whose persistence leads to 
tumor recurrence and metastases, to be abrogated [102]. 
The selection of the right endpoints to consider for efficacy evaluation is another issue that must be 
addressed. Indeed, clinical trials performed with CSC inhibitors have demonstrated that, although 
they can prolong disease-free survival when associated to debulking chemotherapy, their beneficial 
effects are not immediate [103]. Therefore, the Response Evaluation Criteria In Solid Tumors 
(RECIST), and the setup of diagnostic tools that can robustly measure CSC frequency and function 
in human specimens probably require modifications if they are to correctly evaluate the efficacy of 
CSC-directed immunotherapies.  
In conclusion, although the pathway for translating BCSC immunotherapies into every-day clinical 
practice is not straightforward, the identification of BCSC oncoantigens paves the way for the 
development of new therapies that combine BCSC-immunotargeting with debulking chemotherapy 
and/or immune checkpoint inhibitors. We firmly believe that this would ultimately provide an 
effective curative approach for the treatment of breast cancer.  
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Caption to figure 
Figure 1. Pipeline for the identification of BCSC oncoantigens. Breast cancer cell lines are 
cultured as epithelial monolayers (A) or as tumorspheres (B), which are enriched in CSC as assayed 
by flow cytometric analyses for several CSC markers (C). A high-throughput analysis of the 
transcriptome of breast cancer cells and tumorspheres is performed (D), and the differentially 
expressed genes are identified (E). All transcripts that show increased expression in tumorspheres 
are considered as putative BCSC oncoantigens and prioritized according to their association with 
poor prognosis in breast cancer patients in public data sets (F). The top-ranked oncoantigens are 
validated with in vitro studies to verify their role in CSC (G).  Mammary tumor-bearing mice are 
then immunized with DNA vaccines that target the selected oncoantigen (H) and their effects are 
monitored (I).  
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